Abstract: Provided herein are combination therapies comprising GDC-9545 and abemaciclib or ribociclib for treating locally advanced breast cancer or metastatic breast cancer.
Type:
Application
Filed:
August 15, 2023
Publication date:
November 30, 2023
Applicant:
Genentech, Inc.
Inventors:
Ciara METCALFE, Pablo Diego PEREZ-MORENO, Xiaojing WANG
Abstract: Provided herein are combination therapies comprising GDC-9545 and GDC-0077 for treating locally advanced breast cancer or metastatic breast cancer.
Abstract: A method, system, and non-transitory computer readable medium for estimating mechanistic chromatography model uncertainty. A mechanistic model of chromatography that comprises a plurality of parameters is received. For each of the plurality of parameters, a corresponding region of values is identified based on a relationship between values for the plurality of parameters. Each parameter of the plurality of parameters is sampled within the corresponding region of values for each parameter to form a plurality of simulation sets. An uncertainty for the mechanistic model is quantified using the plurality of simulation sets.
Type:
Application
Filed:
August 10, 2023
Publication date:
November 30, 2023
Applicant:
GENENTECH, INC.
Inventors:
Jessica Yang LYALL, Connor James THOMPSON, Sean Mackenzie BURGESS
Abstract: Presently provided are inhibitors of TD02 and IDO1 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.
Abstract: The present disclosure relates to modified mammalian cells having reduced or eliminated expression of certain cellular proteins, CRISPR/Cas9 multiplex knockout strategies for making such cells, and methods of using such cells, e.g., in the context of cell-based therapy or as host cells in the production of a product of interest.
Type:
Application
Filed:
February 28, 2023
Publication date:
November 23, 2023
Applicants:
GENENTECH, INC., HOFFMANN-LA ROCHE INC.
Inventors:
Amy SHEN, Inn Huam Yuk, Peggy Wai No Ko, Shahram Misaghi, Simon Thomas Auslaender, Midori Greenwood-Goodwin, Michael Wilson Laird, Benedikt Alois Claudius Oswald
Abstract: The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
Type:
Application
Filed:
May 1, 2023
Publication date:
November 16, 2023
Applicant:
Genentech, Inc.
Inventors:
Yung-Hsiang KAO, Michael W. LAIRD, Melody Trexler SCHMIDT, Rita L. WONG, Daniel P. HEWITT
Abstract: Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes on a single molecule or located on different molecules. The methods combine efficient, high gene expression level, appropriate assembly, and ease of purification for the heteromultimeric proteins. The invention also provides methods of using these heteromultimeric proteins, and compositions, kits and articles of manufacture comprising these antibodies.
Type:
Application
Filed:
April 7, 2023
Publication date:
November 9, 2023
Applicant:
Genentech, Inc.
Inventors:
Justin SCHEER, Christoph SPIESS, Daniel G. YANSURA
Abstract: The present disclosure relates to techniques for service orchestration within a distributed pod based system. Particularly, aspects are directed to receiving, at a kernel residing on a distributed computing environment, a request to initiate deployment for a subservice or service on the distributed computing environment. The subservice or service has a type, and in order for the subservice or service to be deployed on the distributed computing environment, the type of the subservice or service has to be one that the distributed computing environment is configured to support. In response to receiving the request and the type of the subservice or service being one that the distributed computing environment is configured to support, specified resources are provisioned, and the subservice or service is deployed using a replica of a pod containing the provisioned specified resources and a modified image for the type of the subservice or service.
Abstract: The application disclosed concerns a method of treating pneumonia in a patient who is not mechanically ventilated comprising administering an IL-6 antagonist (e.g. tocilizumab) to the patient in an amount effective to prevent the patient from dying or receiving mechanical ventilation. The disclosure is based on the results of the EM PACTA clinical trial.
Type:
Application
Filed:
March 19, 2021
Publication date:
November 9, 2023
Applicant:
Genentech, Inc.
Inventors:
Shalini V. MOHAN, William George REISS, Hoi Ying Linda YAU, Benjamin Howard KRAMER, Jian HAN
Abstract: In one embodiment, a method includes receiving one or more querying images associated with a container of a pharmaceutical product, each of the one or more querying images being based on a particular angle of the container of the pharmaceutical product, calculating one or more confidence scores associated with one or more defect indications, respectively for the container of the pharmaceutical product, by processing the one or more querying images using a target machine-learning model, and determining a defect indication for the container of the pharmaceutical product from the one or more defect indications based on a comparison between the one or more confidence scores and one or more predefined threshold scores, respectively.
Abstract: The present disclosure provides compositions, methods, and kits for detecting lipolytic activity. In some embodiments, the composition comprises an aqueous assay sample and an organic solvent, wherein the organic solvent comprises 4-methylumbellif-erryl caprylate (MU-C8). Also provided herein are methods for determining the stability of a protein preparation.
Type:
Application
Filed:
August 31, 2021
Publication date:
November 2, 2023
Applicant:
GENENTECH, INC.
Inventors:
Li YI, Adithi Chandrasekhara BHARGAVA, Inn Huam YUK
Abstract: The present disclosure provides methods and systems for high throughput assays for testing immune cell engager molecules and potential immune cell engager molecules. In some embodiments, multiple parameters, for example, in connection with engagement of tumor cells by immune cells such as T cells and in connection with tumor cell death, may be analyzed from the same samples in the assays, and, in some cases, may be analyzed simultaneously. In some embodiments, the methods and systems allow for determining the kinetics of various parameters.
Abstract: The invention relates generally crystalline mesylate salts, crystalline chloride salts and crystalline sulfate salts of the compound (S)-2-(3?-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro- [3,4?-bipyridin]-2?-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one that is an inhibitor of Bruton’s tyrosine kinase. In some aspects, the crystalline salts are single polymorphs.
Abstract: Provided herein are high throughput methods for optimizing and manufacturing various lipid nanoparticle (LNP) compositions and uses thereof. For example, in some embodiments, the present disclosure provides a high-throughput screening method for manufacturing a LNP composition comprising, obtaining at least two intermixable solutions comprising a payload and a plurality of molecules capable of self-assembly and mixing said at least two solutions under a set of controlled conditions, by which injection sequence, speed, volume, phase ratio and mixing duration are varied. In various embodiments, the present disclosure enables optimal encapsulation efficiency, particle size distribution, purification and particle recovery rate, and formulation stability to be determined. The methods disclosed herein enable efficient optimization of manufacturing conditions for preparation of LNP-based therapeutics.
Abstract: The subject matter described herein is directed to antibody-CIDE conjugates (Ab-CIDEs) that target BRM for degradation, to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where BRM degradation is beneficial.
Type:
Application
Filed:
January 19, 2023
Publication date:
October 19, 2023
Applicant:
Genentech, Inc.
Inventors:
Peter Scott DRAGOVICH, Summer A. BAKER DOCKREY, Thomas Harden PILLOW, Donglu ZHANG
Abstract: The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.